StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.33−0.25 (-1.84%)

Close on Nov 18, 2026Market cap $467.45MP/E –Yield –

Fennec Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Fennec Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$1.13M. For fiscal 2025 it was -$6.28M, down 344.6% from the year before. The highest annual figure on record is $2.57M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.28M-344.6%
FY2024Dec 31, 2024$2.57M–
FY2023Dec 31, 2023-$12.77M–
FY2022Dec 31, 2022-$22.59M–
FY2021Dec 31, 2021-$17.22M–
FY2020Dec 31, 2020-$17.89M–
FY2019Dec 31, 2019-$13.01M–
FY2018Dec 31, 2018-$10.41M–
FY2017Dec 31, 2017-$6.95M–
FY2016Dec 31, 2016-$2.87M–
FY2015Dec 31, 2015-$1.89M–
FY2014Dec 31, 2014-$2.88M–
FY2013Dec 31, 2013-$1.93M–
FY2012Dec 31, 2012-$3.62M–
FY2011Dec 31, 2011-$3.44M–
FY2010Dec 31, 2010-$4.60M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.74M–
Q1 FY2026Mar 31, 2026-$119.00K–
Q4 FY2025Dec 31, 2025-$2.55M–
Q3 FY2025Sep 30, 2025-$189.00K–
Q2 FY2025Jun 30, 2025-$2.73M–
Q1 FY2025Mar 31, 2025-$808.00K-105.9%
Q4 FY2024Dec 31, 2024-$934.00K–
Q3 FY2024Sep 30, 2024-$5.20M–
Q2 FY2024Jun 30, 2024-$5.04M–
Q1 FY2024Mar 31, 2024$13.74M–
Q4 FY2023Dec 31, 2023-$1.82M–
Q3 FY2023Sep 30, 2023-$1.02M–
Q2 FY2023Jun 30, 2023-$4.67M–
Q1 FY2023Mar 31, 2023-$5.27M–
Q4 FY2022Dec 31, 2022-$6.14M–
Q3 FY2022Sep 30, 2022-$7.90M–
Q2 FY2022Jun 30, 2022-$5.01M–
Q1 FY2022Mar 31, 2022-$3.55M–
Q4 FY2021Dec 31, 2021-$4.21M–
Q3 FY2021Sep 30, 2021-$4.17M–
Q2 FY2021Jun 30, 2021-$3.92M–
Q1 FY2021Mar 31, 2021-$4.92M–
Q4 FY2020Dec 31, 2020-$3.35M–
Q3 FY2020Sep 30, 2020-$5.86M–
Q2 FY2020Jun 30, 2020-$4.85M–
Q1 FY2020Mar 31, 2020-$3.84M–
Q4 FY2019Dec 31, 2019-$3.65M–
Q3 FY2019Sep 30, 2019-$1.86M–
Q2 FY2019Jun 30, 2019-$4.81M–
Q1 FY2019Mar 31, 2019-$2.68M–
Q4 FY2018Dec 31, 2018-$3.11M–
Q3 FY2018Sep 30, 2018-$2.85M–
Q2 FY2018Jun 30, 2018-$2.67M–
Q1 FY2018Mar 31, 2018-$1.79M–
Q4 FY2017Dec 31, 2017-$2.52M–
Q3 FY2017Sep 30, 2017-$2.19M–
Q2 FY2017Jun 30, 2017-$1.48M–
Q1 FY2017Mar 31, 2017-$771.00K–
Q4 FY2016Dec 31, 2016-$1.15M–
Q3 FY2016Sep 30, 2016-$564.00K–

More Fennec Pharmaceuticals figures

See a number that looks wrong?